<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1309234204
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Clodipan 16 mg and 5 mg
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CANDESARTAN CILEXETIL,AMLODIPINE BESILATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        16,5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        64.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ADAMED Pharma S.A " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ADAMED Pharma S.A 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Aspen Healthcare
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09DB07
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>1. What Clodipan is and what it is used for</strong></p><p>The name of your medicine is Clodipan. The active ingredients are candesartan cilexetil and amlodipine besilate.</p><p>Candesartan belongs to a group of medicines called angiotensin II receptor antagonists. It works by making your blood vessels relax and widen. This helps to lower your blood pressure.</p><p>Amlodipine belongs to a group of medicines called calcium antagonists. It works by relaxing blood vessels, so that blood passes through them more easily.</p><p>This medicine is used for treating high blood pressure (hypertension).</p><p>Since this drug may cause excessively decreased blood pressure it should not be used as a primary drug for the treatment of hypertension.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>2.What you need to know before you take Clodipan Do not take Clodipan:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to amlodipine or to any other calcium antagonists, candesartan cilexetil or any of the other ingredients of this medicine (listed in section 6).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; if you have severe low blood pressure (hypotension)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; if you have narrowing of the aortic heart valve (aortic stenosis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; if you have cardiogenic shock (a condition where your heart is unable to supply enough blood to the body)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from heart failure after a heart attack</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; if you are more than 3 months pregnant (see section Pregnancy and breast-feeding)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe liver disease or biliary obstruction (a problem with the drainage of the bile from the gall bladder)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; concomitant use with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR &lt; 60 ml/min/1.73 m<sup>2</sup>).</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking Clodipan if you have or have had any of the following conditions:</p><p>-&nbsp;&nbsp;&nbsp; recent heart attack</p><p>-&nbsp;&nbsp;&nbsp; heart failure</p><p>-&nbsp;&nbsp;&nbsp; severe increase in blood pressure (hypertensive crisis)</p><p>-&nbsp;&nbsp;&nbsp; low blood pressure (hypotension)</p><p>-&nbsp;&nbsp;&nbsp; you are elderly and your dose needs to be increased</p><p>-&nbsp;&nbsp;&nbsp; liver or kidney problems, or you are on dialysis</p><p>-&nbsp;&nbsp;&nbsp; you have recently had a kidney transplant</p><p>-&nbsp;&nbsp;&nbsp; you are vomiting, have recently had severe vomiting, or have diarrhoea</p><p>-&nbsp;&nbsp;&nbsp; you have a disease of the adrenal glands called Conn&rsquo;s syndrome (also called primary hyperaldosteronism)</p><p>-&nbsp;&nbsp;&nbsp; you have ever had a stroke</p><p>-&nbsp;&nbsp;&nbsp; you are taking any of the following medicines used to treat high blood pressure:</p><p>&bull; an ACE-inhibitor (for example enalapril, lisinopril, ramipril), if you have diabetes- related kidney problems,</p><p>&bull;&nbsp; aliskiren.</p><p>Your doctor may want to see you more often and do some tests if you have any of above conditions.</p><p>Your doctor may check your kidney function, blood pressure and the amount of electrolytes (e.g. potassium) in your blood at regular intervals.</p><p>See also information under the heading &ldquo;Do not take Clodipan&rdquo;.</p><p>If you are going to have an operation, tell your doctor or dentist that you are taking Clodipan. This is because Clodipan, when combined with some anaesthetics, may cause an excessive drop in blood pressure.</p><p>You must tell your doctor if you think that you are (or might become) pregnant. Clodipan is not recommended in early pregnancy and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see section &ldquo;Pregnancy and breast-feeding&rdquo;).</p><p><strong>Children and adolescents</strong></p><p>There is no experience with the use of Clodipan in children and adolescents (below the age of 18 years). Therefore, do not give this medicine to children and adolescents.</p><p><strong>Other medicines and Clodipan</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>Clodipan may affect or be affected by other medicines, such as:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ketoconazole, itraconazole (anti-fungal medicines);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ritonavir, indinavir, nelfinavir (so called protease inhibitors used to treat HIV);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifampicin, erythromycin, clarithromycin (antibiotics);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Hypericum perforatum </em>(St. John&rsquo;s Wort);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; verapamil, diltiazem (heart medicines);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dantrolene (infusion for severe body temperature abnormalities);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; simvastatin (a cholesterol lowering medicine);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other medicines to help lower your blood pressure, including beta-blockers, diazoxide and ACE inhibitors (such as enalapril, captopril, lisinopril or ramipril) or aliskiren (see also information under the headings &ldquo;Do not take Clodipan&rdquo; and &ldquo;Warnings and precautions&rdquo;);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, naproxen, diclofenac, celecoxib or etoricoxib (medicines to relieve pain and inflammation);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acetylsalicylic acid (medicine to relieve pain and inflammation), if you are taking more than 3 g each day;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; potassium supplements or salt substitutes containing potassium (medicines that increase the amount of potassium in your blood)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heparin (a medicine for thinning the blood);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; water capsules (diuretics)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lithium (a medicine for mental health problems);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tacrolimus (used to control your body&rsquo;s immune response, enabling your body to accept the transplanted organ);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cyclosporine (an immunosuppressive drug used mainly after organ transplant to avoid organ rejection).</p><p><strong>Clodipan with food and drink</strong></p><p>Grapefruit and grapefruit juice should not be consumed while taking Clodipan. This is because grapefruit and grapefruit juice can lead to an increase in the blood levels of the active ingredient amlodipine, which can cause an unpredictable increase in the blood pressure lowering effect of Clodipan.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p><strong>Pregnancy</strong></p><p>You must tell your doctor if you think you are (or might become) pregnant. Your doctor will normally advise you to stop taking Clodipan before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Clodipan.</p><p>Clodipan is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.</p><p><strong>Breast-feeding</strong></p><p>Amlodipine has been shown to pass into breast milk in small amounts.</p><p>Tell your doctor if you are breast-feeding or about to start breast-feeding. Clodipan is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast- feed, especially if your baby is newborn or was born prematurely.</p><p><strong>Driving and using machines</strong></p><p>Clodipan may have moderate influence on your ability to drive or use machines. If the capsules make you feel sick, dizzy or tired, or give you a headache, do not drive or use machines and contact your doctor immediately.</p><p><strong>Clodipan contains lactose monohydrate</strong></p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>3.&nbsp;&nbsp;How to take Clodipan&nbsp;</strong></p><p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Usually recommended dose is one capsule per day.</p><p>Patients receiving candesartan and amlodipine as separate products can instead receive capsules of Clodipan containing the same components in the same doses.</p><p><strong>If you take more Clodipan than you should</strong></p><p>Taking too many capsules may cause your blood pressure to become low or even dangerously low. You may feel dizzy, lightheaded, faint or weak. If blood pressure drop is severe enough shock can occur.</p><p>Your skin could feel cool and clammy and you could lose consciousness. Seek immediate medical attention if you have taken more capsules than prescribed.</p><p><strong>If you forget to take Clodipan</strong></p><p>If you forget to take a capsule, leave out that dose completely. Take your next dose at the right time. Do not take a double dose to make up for a forgotten dose.</p><p><strong>If you stop taking Clodipan</strong></p><p>Your doctor will advise you how long to take your medicine. Your condition may return if you stop using your medicine before you are advised. Therefore do not stop taking Clodipan without first talking to your doctor.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>4.&nbsp;Possible side effects</strong></p><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Stop taking Clodipan and seek medical help immediately if you have any of the following reactions:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden wheeziness, chest pain, shortness of breath or difficulty in breathing;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of eyelids, face or lips;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the tongue and throat which causes great difficulty in breathing;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe skin reactions including intense skin rash, hives, reddening of the skin over your whole body, severe itching, blistering, peeling and swelling of the skin, inflammation of mucous membranes (Stevens Johnson Syndrome, toxic epidermal necrolysis ) or other allergic reactions;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart attack, abnormal heart beat;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflamed pancreas which may cause severe abdominal and back pain accompanied with feeling very unwell.</p><p><strong>Other possible side effects</strong></p><p>Since Clodipan is a combination of two active substances, the side effects that have been reported are linked either to the use of amlodipine or candesartan.</p><p><strong>Side effects linked to the use of candesartan</strong></p><p>Candesartan may cause a reduction in number of white blood cells. Your resistance to infection may be decreased and you may notice tiredness, an infection or a fever. If this happens contact your doctor. Your doctor may occasionally do blood tests to check whether Clodipan has had any effect on your white blood cells (agranulocytosis).</p><p>Common (may affect up to 1 in 10 people):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling dizzy/spinning sensation</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; respiratory infection</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure - this may make you feel faint or dizzy</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in blood test results:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an increased amount of potassium in your blood, especially if you already have kidney problems or heart failure. If this is severe you may notice tiredness, weakness, irregular heart beat or pins and needles</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; effects on how your kidneys work, especially if you already have kidney problems or heart failure. In very rare cases, kidney failure may occur.</p><p>Very rare (may affect up to 1 in 10,000 people):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the face, lips, tongue and/or throat</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a reduction in your red or white blood cells - you may notice tiredness, an infection or a fever</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash, lumpy rash (hives)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; back pain, pain in joints and muscles</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in how your liver is working, including inflammation of the liver (hepatitis) - you may notice tiredness, yellowing of your skin and the whites of your eyes and flu-like symptoms</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>-&nbsp;&nbsp;&nbsp; changes in blood test results:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a reduced amount of sodium in your blood - if this is severe then you may notice weakness, lack of energy or muscle cramps.</p><p>Not known (frequency cannot be estimated from the available data)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p><strong>Side effects linked to the use of amlodipine</strong></p><p>The following side effects have been reported. If any of these cause you problems or if they last for more than one week, you should contact your doctor.</p><p>Very common (may affect more than 1 in 10 people):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; oedema (fluid retention)</p><p>Common (may affect up to 1 in 10 people ):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache, dizziness, sleepiness (especially at the beginning of treatment)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; palpitations (awareness of your heart beat), flushing</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal pain, feeling sick (nausea)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; altered bowel habits, diarrhoea, constipation, indigestion,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness, weakness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; visual disturbances, double vision</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle cramps</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ankle swelling</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dyspnoea</p><p>Uncommon (may affect up to 1 in 100 people):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mood changes, anxiety, depression, sleeplessness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trembling, taste abnormalities, fainting</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; numbness or tingling sensation in your limbs, loss of pain sensation</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ringing in the ears</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sneezing/running nose caused by inflammation of the lining of the nose (rhinitis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry mouth, vomiting (being sick)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hair loss, increased sweating, itchy skin, red patches on skin, skin discolouration</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disturbance in passing urine, increased need to urinate at night, increased number of times of passing urine</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inability to obtain an erection, discomfort or enlargement of the breasts in men (gynecomastia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain, feeling unwell</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint or muscle pain, back pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight increase or decrease</p><p>Rare (may affect up to 1 in 1,000 people):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; confusion</p><p>Very rare (may affect up to 1 in 10,000 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased numbers of white blood cells, decrease in blood platelets which may result in unusual bruising or easy bleeding</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; excess sugar in blood (hyperglycaemia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a disorder of the nerves which can cause weakness, tingling or numbness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the gums</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal bloating (gastritis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal liver function, inflammation of the liver (hepatitis), yellowing of the skin (jaundice), liver enzyme increase which may have an effect on some medical tests</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased muscle tension</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of blood vessels, often with skin rash</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sensitivity to light</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disorders combining rigidity, tremor and/or movement disorders</p><p>Not known (frequency cannot be estimated from the available data):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trembling, rigid posture, masklike face, slow movements and a shuffling, unbalanced walk, toxic epidermal necrolysis.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>5.How to store Clodipan&nbsp;</strong></p><p>Do not store above 30 &ordm;C.</p><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton/blister after EXP. The expiry date refers to the last day of that month.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Clodipan contains</strong></p><p>The active substances are candesartan cilexetil and amlodipine.</p><p>Clodipan 8 mg/5 mg hard capsules</p><p>Each capsule contains 8 mg candesartan cilexetil and 5 mg amlodipine equivalent to 6.935 mg amlodipine besilate.</p><p>Clodipan 8 mg/10 mg hard capsules</p><p>Each capsule contains 8 mg candesartan cilexetil and 10 mg amlodipine equivalent to 13.87 mg amlodipine besilate.</p><p>Clodipan 16 mg/5 mg hard capsules</p><p>Each capsule contains 16 mg candesartan cilexetil and 5 mg amlodipine equivalent to 6.935 mg amlodipine besilate.</p><p>Clodipan 16 mg/10 mg hard capsules</p><p>Each capsule contains 16 mg candesartan cilexetil and 10 mg amlodipine equivalent to 13.87 mg amlodipine besilate.</p><p>The other ingredients are: lactose monohydrate, maize starch, carmellose calcium, macrogol type 8000, hydroxypropylcellulose/type: EXF, 250-800 cps, hydroxypropylcellulose /type: LF 65-175 cps, magnesium stearate.</p><p>Capsule shell (8 mg/5 mg, 8 mg/10 mg): quinoline yellow (E 104), iron oxide yellow (E 172), titanium dioxide (E 171), gelatin</p><p>Capsule shell (16 mg/5 mg): quinoline yellow (E 104), titanium dioxide (E 171), gelatin Capsule shell (16 mg/10 mg): titanium dioxide (E 171), gelatin</p><p>Printing ink (8 mg/10 mg, 16 mg/5 mg): shellac (E904), iron oxide black (E172), propylene glycol, ammonia solution concentrated, potassium hydroxide</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Clodipan 8 mg/5 mg hard capsules: hard gelatin capsules, size 3, with a white opaque body and dark yellow cap, filled with white to off white granules

Clodipan 8 mg/10 mg hard capsules: hard gelatin capsules, size 1, with a white opaque body with black imprint CAN 8 and yellow cap with black imprint AML 10, filled with white to off white granules
 
Clodipan 16 mg/5 mg hard capsules: hard gelatin capsules, size 1, with a white opaque body with black imprint CAN 16 and pale yellow cap with black imprint AML 5, filled with white to off white granules

Clodipan 16 mg/10 mg hard capsules: hard gelatin capsules, size 1, a with white opaque body and white opaque cap, filled with white to off white granules

Pack size: 28 hard capsules
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder and Manufacturer </strong></p><p><strong>Marketing Authorisation Holder:</strong><br />Aspen Healthcare Malta Limited<br />89, Level 0<br />Triq is-Siggiewi<br />Is-Siggiewi SGW 2021<br />Malta</p><p><strong>Manufacturer:</strong><br />Adamed Pharma S.A.<br />ul. Marszałka J&oacute;zefa Piłsudskiego 5<br />95-200 Pabianice<br />Poland</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in {September/2023} version {2}.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>1.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>ما هو كلوديبان وما هي دواعي استخدامه</strong></p><p dir="RTL">اسم هذا الدواء هو كلوديبان.المواد الفعالة في هذا الدواء هي كانديسارتان سيليكسيتيل وأملوديبين بيسيلات.</p><p dir="RTL">ينتمي كانديسارتان إلى مجموعة الأدوية التي تسمى مضادات مستقبلات ويعمل عن طريق II الأنجيوتنسين جعل الأوعية الدموية تسترخي وتتوسع. وهذا يساعد في خفض ضغط الدم.</p><p dir="RTL">ينتمي أملوديبين إلى مجموعة الأدوية التي تسمى مضادات الكالسيوم.</p><p dir="RTL">وهو يعمل على استرخاء الأوعية الدموية، ليمر الدم من خلالها بشكل أكثر سهولة.</p><p dir="RTL">يستخدم هذا الدواء لعلاج ارتفاع ضغط الدم.</p><p dir="RTL">بما أن لهذا الدواء القدرة على خفض ضغط الدم بشكل مفرط، لا ينبغي أن يستخدم هذا الدواء كعلاج أولي لارتفاع ضغط الدم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>2.&nbsp;</strong><strong>ما الذي يجب أن تعرفه قبل تناول كلوديبان</strong></p><p dir="RTL"><strong>لا تتناول كلوديبان</strong><strong> :</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابا بحساسية لمادة أملوديبين أو أي مضادات كالسيوم أخرى، أو كانديسارتان سيليكسيتيل أو أي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابا بانخفاض شديد في ضغط الدم (هبوط ضغط الدم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابا بصمام القلب الأبهري (تضيق الأبهري)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابا بصدمة قلبية المنشأ (حالة لا يتمكن بها القلب من إمداد الجسم بكمية دم كافية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من فشل قلبي بعد الإصابة بأزمة قلبية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملاً وتخطيتي الشهر الثالث من الحمل (راجعي قسم الحمل والرضاعة الطبيعية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابا بمرض كبدي حاد أو انسداد صفراوي (مشكلة تؤثر على تفريغ الصفراء من الحويصلة الصفراوية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُمنع الاستخدام المتزامن مع المنتجات التي تحتوي أليسكيرين لدى المرضى المصابين بداء السكري أو القصور الكلوي (معدل الترشيح الكبيبي &lt; 60 مل/دقيقة/ 1.73 م <sup>2</sup>)</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي قبل تناول كلوديبان إذا كنت مصابا أو سبقت لك الإصابة بأي من الحالات التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أزمة قلبية حديثة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل القلب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع حاد في ضغط الدم (نوبة فرط الضغط)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم (هبوط الضغط)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت شخصا مسنا وتحتاج لزيادة الجرعة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابا بمشاكل كبدية أو كلوية، أو كنت تخضع لديلزة الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا خضعت مؤخراً لزرع كلية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابا بنوبة قيء، أو أصبت مؤخراً بنوبة قيء حادة، أو كنت مصابا بالإسهال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابا بمرض بالغدد الكظرية، يسمى متلازمة كون (تسمى أيضا فرط ألدوستيرونية أولي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا سبقت لك الإصابة بسكتة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أي من الأدوية التالية المستخدمة لعلاج ارتفاع ضغط الدم:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبط الإنزيم المحول للأنجيوتنسين (ACE) (على سبيل المثل إنالابريل، ليزينوبريل، راميبريل)، إذا كنت مصابا بمشاكل كلوية مرتبطة بداء السكري،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أليسكيرين.</p><p dir="RTL">قد يرغب طبيبك في رؤيتك أكثر وإجراء بعض التحاليل إذا كنت مصابا بأي من الحالات أعلاه.</p><p dir="RTL">قد يفحص طبيبك وظائف الكلى وضغط الدم وكمية الإلكتروليات لديك (على سبيل المثال، البوتاسيوم) في دمك على فترات منتظمة.</p><p dir="RTL">راجع أيضا المعلومات تحت عنوان &quot;لا تتناول كلوديبان&quot;.</p><p dir="RTL">إذا كنت ستخضع لعملية جراحية، اخبر الطبيب أو طبيب الأسنان أنك تتناول كلوديبان. هذا لأنه عند الجمع بين كلوديبان وأدوية تخدير محددة، قد يتسبب ذلك في انخفاض مفرط في ضغط الدم.</p><p dir="RTL">يجب أن تخبري طبيبك إذا كنتِ تظنين أنك حامل أو قد تصبحين حاملاً. لا يوصى بتناول كلوديبان في مراحل الحمل الأولى ويجب عدم تناوله إذا تخطيتي الشهر الثالث من الحمل، حيث قد يتسبب ذلك في ضرر بالغ لجنينك إذا استخدم في هذه المرحلة (راجعي قسم &quot;الحمل والرضاعة الطبيعية&quot;) .</p><p><strong>الأطفال والمراهقون</strong></p><p>لم تجرى تجارب استخدام كلوديبان على الأطفال والمراهقين (أقل من 18 عاما).</p><p dir="RTL">لذا، لا تعط هذا الدواء للأطفال والمراهقين.</p><p dir="RTL"><strong>الأدوية الأخرى وكلوديبان</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إن كنت تتناول أو تناولت مؤخراً أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">قد يؤثر كلوديبان على مفعول بعض الأدوية الأخرى أو يتأثر بها، مثل:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كيتوكونازول أو إيتراكونازول (أدوية مضادة للفطريات)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريتونافير، أو إندينافير، أو نلفينافير (تسمى مثبطات البروتييز وهي تستخدم في علاج فيروس نقص المناعي البشري (HIV)).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين، إريثرومايسين، كلاريثرومايسين <strong>(مضادات حيوية</strong><strong> </strong><strong>)</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هايبيريكم بيرفراتم (نبتة القديس يوحنا المثقبة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فيراباميل، ديلتيازيم (أدوية لعلاج القلب)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دانترولين (تسريب لعلاج اضطرابات حرارة الجسم الحادة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيمفاستاتين (دواء لخفض الكوليسترول)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية أخرى لخفض ضغط الدم، تتضمن حاصرات بيتا، وديازوكسيد ومثبطات الإنزيم المحول للأنجيوتنسين (ACE) (مثل إنالابريل، كابتوبريل، ليزينوبريل أو راميبريل) أو أليسكيرين (انظر أيضا المعلومات تحت العنوانين &quot;لا تتناول كلوديبان&quot; و&quot;التحذيرات والاحتياطات&quot;)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الالتهاب اللاستيرويدية (NSAID) مثل إيبوبروفين، نابروكسين، ديكلوفيناك، سيليكوكسيب، إيتوريكوكسيب (أدوية لتسكين الآلام والالتهابات)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمض أسيتيل ساليسيليك (دواء لتسكين الآلام والالتهابات)، إذا كنت تتناول أكثر من 3 غ يوميا ،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مكملات البوتاسيوم أو بدائل الملح التي تحتوي على البوتاسيوم (أدوية لرفع كمية البوتاسيوم في الدم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هيبارين (دواء لترقيق الدم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أقراص الماء (مدرات البول)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ليثيوم (دواء لعلاج مشاكل الصحة النفسية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تاكروليماس (يُستخدم للتحكم في استجابة جسمك المناعية، فتساعده على قبول العضو المزروع)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيكلوسبورين (دواء كابت للمناعة يستخدم بشكل رئيسي بعد زراعة الأعضاء لتجنب رفض العضو).</p><p dir="RTL"><strong>كلوديبان مع الطعام و الشراب</strong></p><p dir="RTL">يجب الامتناع عن تناول الغريب فروت وعصير الغريب فروت أثناء العلاج بكلوديبان. فقد يتسبب الغريب فروت وعصير الغريب فروت في رفع مستويات الدم من مادة أملوديبين الفعالة، مما قد يتسبب في زيادة غير متوقعة في التأثير الخافض لضغط الدم الذي يحدثه كلوديبان.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنتِ حاملاً أو ترضعين رضاعة طبيعية، أو تعتقدين أنكِ قد تكونين حاملاً أو تخططين للحمل، اطلبي المشورة من طبيبك أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL"><strong>الحمل</strong></p><p dir="RTL">يجب أن تخبري طبيبك إذا كنتِ تظنين أنك حامل أو قد تصبحين حاملاً. سينصحك طبيبك عادة بالتوقف عن تناول كلوديبان قبل أن تصبحي حاملا أو بمجرد أن تعرفي أنك حامل وسيخبركِ بتناول دواء آخر غير كلوديبان.</p><p dir="RTL">لا يُوصى بتناول كلوديبان في مراحل الحمل الأولى، ويجب الامتناع عن تناوله إذا تخطيتي الشهر الثالث من الحمل ، حيث قد يتسبب في ضرر بالغ لجنينك إذا استخدم بعد الشهر الثالث من الحمل.</p><p dir="RTL"><strong>الرضاعة الطبيعية</strong></p><p dir="RTL">قد تبين أن أملوديبين يمر إلى حليب الثدي بكميات ضئيلة.</p><p dir="RTL">أخبري طبيبك إذا كنتِ ترضعين طفلك رضاعة طبيعية أو على وشك البدء فيها. لا يُوصى بتناول كلوديبان للأمهات المرضعات، وقد يختار لكِ الطبيب علاجا آخراً إذا كنتِ تودين أن ترضعي طفلك رضاعة طبيعية، على الأخص إذا كان طفلك حديث الولادة أو وُلد مبكراً (مبتسراً).</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يُحدث كلوديبان تأثيراً متوسطا على قدرتك على القيادة أو استخدام الآلات. إذا شعرت بعد تناول الأقراص بالغثيان، أو الدوّار، أو الإجهاد، أو أصبت بالصداع، امتنع عن القيادة أو استخدام الآلات واتصل بطبيبك على الفور.</p><p dir="RTL"><strong>يحتوي كلوديبان على لاكتوز أحادي الهيدرات</strong><strong>.</strong></p><p dir="RTL">إذا أخبرك طبيبك أنك تعاني من حساسية مفرطة لبعض أنواع السكر، اتصل بطبيبك قبل تناول هذا المنتج الدوائي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>3.</strong><strong>كيفية تناول كلوديبان</strong></p><p dir="RTL">تناول هذا الدواء دائما على النحو الذي وصفه لك طبيبك أو الصيدلي. استشر طبيبك أو الصيدلي إذا لم تكن متأكدًا.</p><p dir="RTL">يُوصى عادة بتناول جرعة من كبسولة واحدة يومياً .</p><p dir="RTL">يمكن للمرضى الذين يتلقون كانديسارتان وأملوديبين كمنتجات منفصلة أن يتناولوا بدلاً من ذلك كبسولات كلوديبان التي تحتوي نفس المكونين بالجرعات نفسها.</p><p dir="RTL"><strong>في حالة تناولك جرعة أكبر مما ينبغي من كلوديبان</strong></p><p dir="RTL">قد يتسبب تناول جرعة أكبر مما ينبغي في انخفاض ضغط الدم لديك أو حتى انخفاضه بشكل خطير. قد تشعر بالدوّار، أو الدوخة، أو الإغماء أو الضعف. في حالة الانخفاض الحاد في ضغط الدم، قد تحدث لك صدمة. قد تصبح بشرتك باردة ومتندية بالعرق، وقد تفقد الوعي. اطلب عناية طبية على الفور إذا تناولت الكبسولات بكمية أكبر من الموصوفة لك.</p><p dir="RTL"><strong>إذا نسيت تناول كلوديبان</strong></p><p dir="RTL">إذا نسيت تناول كبسولة، فوّت هذه الجرعة بالكامل. تناول الجرعة التالية في الموعد المعتاد. لا تتناول جرعة مضاعفة لتعويض الجرعة التي نسيتها.</p><p dir="RTL"><strong>في حال الانقطاع عن تناول كلوديبان</strong></p><p dir="RTL">سيخبرك طبيبك بالفترة التي ينبغي عليك تناول العلاج خلالها . قد تعاودك الحالة إذا انقطعت عن تناول الدواء قبل أن يشير عليك الطبيب بذلك .</p><p dir="RTL">لذا لا تنقطع عن تناول كلوديبان بدون التحدث إلى طبيبك أولا .</p><p dir="RTL">إن كان لديك أي استفسارات أخرى حول استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>4.</strong><strong>الآثار الجانبية المحتملة</strong></p><p dir="RTL">مثل جميع الأدوية يمكن لهذا الدواء أن يسبب آثاراً جانبية، على الرغم من أنه ليس بالضرورة أن يعاني منها الجميع.</p><p dir="RTL">توقف عن تناول كلوديبان واطلب مساعدة طبية على الفور إذا ظهرت عليك أي من ردود الفعل التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أزيز مفاجئ، ألم بالصدر، ضيق التنفس أو صعوبة التنفس؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الجفون أو الوجه أو الشفتين؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم اللسان والحلق مما قد يتسبب في صعوبة بالغة في التنفس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات جلدية شديدة مثل طفح جلدي شديد، شرى، احمرار جلد الجسم بالكامل، حكة شديدة، ظهور بثور، تقشر وتورم الجلد، التهاب الأغشية المخاطية (متلازمة ستيفنز جونسون، انحلال الأنسجة المتموتة البشروية التسممي) أو ردود فعل تحسسية أخرى،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أزمة قلبية، اضطراب ضربات القلب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس، مما قد يتسبب في ألم حاد في البطن والظهر يصاحبه شعور باعتلال شديد.</p><p dir="RTL"><strong>الآثار الجانبية الأخرى المحتملة</strong></p><p dir="RTL">نظراً لكون كلوديبان مزيجا من مادتين فعالتين، فإن الآثار الجانبية التي وردت في التقارير ترتبط إما باستخدام أملوديبين أو كانديسارتان.</p><p dir="RTL"><strong>الآثار الجانبية المرتبطة باستخدام كانديسارتان</strong></p><p dir="RTL">قد يتسبب كانديسارتان في انخفاض عدد خلايا الدم البيضاء. قد تنخفض مقاومتك للعدوى وقد تلاحظ شعور بالإجهاد، أو حدوث عدوى، أو حمى. في حالة حدوث ذلك، اتصل بالطبيب. قد يطلب الطبيب في بعض الأحيان إجراء اختبارات الدم لمعرفة إذا كان هناك أي تأثير لكلوديبان على خلايا الدم البيضاء لديك (ندرة المحببات).</p><p dir="RTL"><strong>شائعة (قد تؤثر على 1 من كل 10 أشخاص):</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالدوخة أو الدوّار</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى تنفسية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم، قد يشعرك ذلك بالدوخة أو الدوّار.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في نتائج فحوصات الدم:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع كمية البوتاسيوم في الدم، على الأخص إذا كنت مصابا بالفعل بمشاكل كلوية أو فشل قلبي. وإذا كان حاداً، قد تلاحظ شعور بالإجهاد والضعف و عدم انتظام ضربات القلب أو وخز دبابيس وإبر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهور آثار على كيفية عمل الكلى، على الأخص إذا كنت مصابا بالفعل بمشاكل كلوية أو فشل قلبي. في حالات نادرة للغاية، قد يحدث فشل كلوي.</p><p dir="RTL"><strong>نادرة جداً (قد تؤثر على 1 من كل 10000 شخص):</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه، والشفتين، واللسان، و/أو الحلق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم الحمراء أو البيضاء- قد تلاحظ شعور بالإجهاد، أو حدوث عدوى أو حمى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي، طفح جلدي مصحوب بتورم (شرى)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالظهر، ألم بالمفاصل والعضلات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في كيفية عمل الكبد، بما في ذلك التهاب الكبد (الالتهاب الكبدي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تلاحظ شعور بالإجهاد، اصفرار البشرة وبياض العينين وأعراض تشبه الإنفلونزا</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في نتائج فحوصات الدم:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض كمية الصوديوم في الدم، وإ ذا كانت حادة، قد تلاحظ شعور بالضعف، وانخفاض الطاقة وتشنجات عضلية.</p><p dir="RTL"><strong>غير معروف (لا يمكن تقدير مدى التكرار من البيانات المتوفرة):</strong></p><p dir="RTL">- إسهال</p><p dir="RTL"><strong>الآثار الجانبية المرتبطة باستخدام أملوديبين</strong></p><p dir="RTL">وردت الآثار الجانبية التالية في التقارير. إذا تسببت أي منها بمشاكل أو استمرت لأكثر من أسبوع واحد، يجب عليك الاتصال بالطبيب.</p><p dir="RTL"><strong>شائعة جداً (قد تؤثر على أكثر من 1 من كل 10 أشخاص):</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وذمة (احتباس السوائل)</p><p dir="RTL"><strong>شائعة (قد تؤثر على 1 من كل 10 أشخاص)</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع، دوّار، نعاس (على الأخص في بداية العلاج)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خفقان (الشعور بضربات القلب)، احمرار وسخونة الوجه</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالبطن، رغبة في القيء (غثيان)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير في عادات التبرز، إسهال، إمساك، عسر هضم،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إجهاد، ضعف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات بصرية، ازدواج الرؤية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنجات عضلية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الكاحلين،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس</p><p dir="RTL"><strong>غير شائعة (قد تؤثر على 1 من كل 100 شخص):</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير المزاج، قلق، اكتئاب، أرق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتجاف، اضطرابات التذوق، إغماء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بخدر أو وخز في الأطراف، فقدان الشعور بالألم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طنين في الأذن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عطس/رشح الأنف نتيجة لالتهاب بطانة الأنف (التهاب الأنف)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الفم، قيء (الإعياء).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سقوط الشعر، زيادة التعرق، حكة بالجلد، بقع حمراء على الجلد، تغير لون الجلد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب في التبول، زيادة الاحتياج إلى التبول ليلاًّ، زيادة عدد مرات التبول</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة على الانتصاب، شعور بعدم الارتياح أو تضخم الثديين لدى الرجال (تثدي الرجال)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم، شعور بالاعتلال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالمفاصل أو العضلات، ألم بالظهر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة أو انخفاض الوزن</p><p dir="RTL"><strong>نادرة (قد تؤثر على 1 من كل 1,000 شخص):</strong></p><p dir="RTL">- ارتباك</p><p dir="RTL"><strong>نادرة جداً </strong><strong>)</strong><strong>قد تؤثر على 1 من كل 10000 شخص</strong><strong>(</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم البيضاء، انخفاض عدد الصفائح الدموية، مما قد ينتج عنه ظهور كدمات غير معتادة أو النزيف بسهولة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط سكر الدم (ارتفاع سكر الدم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب عصبي قد يتسبب في الشعور بالضعف، أو الوخز أو الخدر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم اللثة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتفاخ البطن (التهاب المعدة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اختلال وظائف الكبد، التهاب الكبد (الالتهاب الكبدي)، اصفرار الجلد (اليرقان)، ارتفاع الإنزيمات الكبدية مما قد يؤثر على نتائج بعض التحاليل الطبية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة التوتر العضلي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأوعية الدموية، مصحوب غالبا بطفح جلدي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحساسية من الضوء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات تجمع ما بين التصلب، والارتجاف و/أو الاضطرابات الحركية</p><p dir="RTL"><strong>غير معروف (لا يمكن تقدير مدى التكرار من البيانات المتوفرة):</strong></p><p dir="RTL">- رعشة، تصلب وضعية الجسم، وجه يشبه القناع، بطء الحركة و ارتباك وعدم توازن السير، انحلال الأنسجة المتموتة البشروية التسممي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>5.</strong><strong>كيفية تخزين كلوديبان</strong></p><p dir="RTL">لا يحفظ في درجة حرارة أعلى من 30 درجة مئوية</p><p dir="RTL">يُحفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية الموضح على العلبة الكرتونية الخارجية/الشريط بعد عبارة &quot;تاريخ انتهاء الصلاحية&quot; &nbsp;(EXP). يشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر.</p><p dir="RTL">لا تتخلص من أي أدوية في ماء الصرف الصحي أو مع المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه الإجراءات في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات كلوديبان</strong></p><p dir="RTL">المادتان الفعالتان هما كانديسارتان سيليكسيتيل وأملوديبين.</p><p dir="RTL">كلوديبان 8 ملجم/ 5 ملجم كبسولات صلبة</p><p dir="RTL">تحتوي كل كبسولة على 8 ملجم كانديسارتان سيليكسيتيل و 5 ملجم أملوديبين، بما يكافئ 6.935 ملجم بيسيلات أملوديبين.</p><p dir="RTL">كلوديبان 8 ملجم/ 10 ملجم كبسولات صلبة</p><p dir="RTL">تحتوي كل كبسولة على 8 ملجم كانديسارتان سيليكسيتيل و 10 ملجم أملوديبين، بما يكافئ 13.87 ملجم بيسيلات أملوديبين.</p><p dir="RTL">كلوديبان 16 ملجم/ 5 ملجم كبسولات صلبة</p><p dir="RTL">تحتوي كل كبسولة على 16 ملجم كانديسارتان سيليكسيتيل و 5 ملجم أملوديبين، بما يكافئ 6.935 ملجم بيسيلات أملوديبين.</p><p dir="RTL">كلوديبان 16 ملجم/ 10 ملجم كبسولات صلبة</p><p dir="RTL">تحتوي كل كبسولة على 16 ملجم كانديسارتان سيليكسيتيل و 10 ملجم أملوديبين، بما يكافئ 13.87 ملجم بيسيلات أملوديبين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المكونات الأخرى هي: لاكتوز أحادي الهيدرات، نشا ذرة، كارميلوز الكاليسيوم، ماكروغول فئة 8000 ، هيدروكسي بروبيل السليولوز/فئة: إي إكس إف <strong>250 - 800 سي بي إس،</strong> هيدروكسي بروبيل السليولوز /فئة: إل إف <strong>65 - 175 سي بي إس</strong>، ستيارات المغنيسيوم.</p><p dir="RTL">أغلفة الكبسولات (8 ملجم/ 5 ملجم ، 8 ملجم/ 10 ملجم): كينولين أصفر (إي 104)، أكسيد الحديد الأصفر (إي 172)، ثاني أكسيد التيتانيوم (إي )171 ، جيلاتين</p><p dir="RTL">غلاف الكبسولات (16 ملجم/ 5 ملجم): كينولين أصفر (إي 104)، ثاني أكسيد التيتانيوم (إي 171)، جيلاتين</p><p dir="RTL">غلاف الكبسولات (16 ملجم/ 10 ملجم): ثاني أكسيد التيتانيوم (إي 171)، جيلاتين</p><p dir="RTL">حبر الطباعة (8 ملجم/ 10 ملجم، 16 ملجم/ 5 ملجم): شيلاك (إي 904)، أكسيد الحديد الأسود (إي 172)، بروبيلين جليكول، محلول أمونيا مركز، هيدروكسيد بوتاسيوم</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كلوديبان 8 ملجم/ 5<strong> </strong>ملجم كبسولات صلبة: كبسولات جيلاتينية صلبة، مقاس 3 ، جسم أبيض غير شفاف وغطاء أصفر داكن، مملوءة بحبيبات لونها ما بين الأبيض إلى الأبيض المائل للصفرة</p><p dir="RTL">كلوديبان 8 ملجم/ 10 ملجم كبسولات صلبة: كبسولات جيلاتينية صلبة، مقاس 1، جسم أبيض غير شفاف مطبوع عليه <strong>&quot; CAN 8 &quot;</strong> باللون الأسود، وغطاء أصفر مطبوع عليه <strong>&quot; </strong><strong>AML 10</strong><strong> &quot;</strong> باللون الأسود، مملوءة بحبيبات لونها ما بين الأبيض إلى الأبيض المائل للصفرة</p><p dir="RTL">كلوديبان 16 ملجم/ 5 ملجم كبسولات صلبة: كبسولات جيلاتينية صلبة، مقاس 1، جسم أبيض غير شفاف مطبوع عليه<strong> &quot; CAN 16 &quot;</strong> باللون الأسود، وغطاء أصفر باهت مطبوع عليه <strong>&quot; </strong><strong>AML 5</strong><strong> &quot;</strong> باللون الأسود، مملوءة بحبيبات لونها ما بين الأبيض إلى الأبيض المائل للصفرة</p><p dir="RTL">كلوديبان 16 ملجم/ 10 ملجم كبسولات صلبة: كبسولات جيلاتينية صلبة، مقاس 1 ، جسم أبيض غير شفاف وغطاء أبيض غير شفاف، مملوءة بحبيبات لونها ما بين الأبيض إلى الأبيض المائل للصفرة</p><p dir="RTL">حجم العبوة: 28 كبسولة صلبة</p><p dir="RTL">قد لا تكون جميع أحجام العبوات مسوقة في بلدك.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك حق التسويق والمُصَّنع</strong></p><p dir="RTL"><strong>مالك حق التسويق</strong><strong>:</strong></p><p dir="RTL">أسبن هيلثكير مالطا المحدودة</p><p dir="RTL">89 ، الطابق 0</p><p dir="RTL">شارع سيغيوي</p><p dir="RTL">سيغيوي، SGW2021</p><p dir="RTL">مالطا</p><p dir="RTL"><strong>المُصَّنع</strong><strong>:</strong></p><p dir="RTL">أداميد فارما إس. إيه</p><p dir="RTL">يو إل. مارشالكا يوزيفا بيلسيو دسكييجو 5</p><p dir="RTL">95-200 بابيانتسزي</p><p dir="RTL">بولندا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة لهذه النشرة في {سبتمبر / 2023}، النسخة {2}
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Clodipan 8 mg/5 mg hard capsules 
Clodipan 8 mg/10 mg hard capsules 
Clodipan 16 mg/5 mg hard capsules 
Clodipan 16 mg/10 mg hard capsules
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Clodipan 8 mg/5 mg hard capsules
Each capsule contains 8 mg candesartan cilexetil and 5 mg amlodipine equivalent to 6.935 mg amlodipine besilate.

Clodipan 8 mg/10 mg hard capsules
Each capsule contains 8 mg candesartan cilexetil and 10 mg amlodipine equivalent to 13.87 mg amlodipine besilate.

Clodipan 16 mg/5 mg hard capsules
Each capsule contains 16 mg candesartan cilexetil and 5 mg amlodipine equivalent to 6.935 mg amlodipine besilate.

Clodipan 16 mg/10 mg hard capsules
Each capsule contains 16 mg candesartan cilexetil and 10 mg amlodipine equivalent to 13.87 mg amlodipine besilate.

Excipient with known effect 
Clodipan 8 mg/5 mg hard capsules
Each capsule contains 101.95 mg of lactose monohydrate.

Clodipan 8 mg/10 mg hard capsules
Each capsule contains 211.90 mg of lactose monohydrate.

Clodipan 16 mg/5 mg hard capsules
Each capsule contains 203.90 mg of lactose monohydrate.

Clodipan 16 mg/10 mg hard capsules
Each capsule contains 203.90 mg of lactose monohydrate. 
For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard capsule

Clodipan 8 mg/5 mg hard capsules: hard gelatin capsules, size 3, with a white opaque body and dark yellow cap, filled with white to off white granules.

Clodipan 8 mg/10 mg hard capsules: hard gelatin capsules, size 1 with a white opaque body with black imprint CAN 8 and yellow cap with black imprint AML 10, filled with white to off white granules.

Clodipan 16 mg/5 mg hard capsules: hard gelatin capsules, size 1 with a white opaque body with black imprint CAN 16 and pale yellow cap with black imprint AML 5, filled with white to off white granules.

Clodipan 16 mg/10 mg hard capsules: hard gelatin capsules, size 1 with a white opaque body and white opaque cap, filled with white to off white granules.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hypertension</p><p>Since this drug may cause excessively decreased blood pressure, this drug should not be used as an initial therapy for hypertension.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>The recommended dose of Clodipan is 1 capsule per day.</p><p>The fixed dose combination is not suitable for initiation therapy. Dose adjustment, if necessary, should be done with the individual components</p><p>Before switching to Clodipan patients should be controlled on stable doses of the individual components taken at the same time.</p><p>The dose of Clodipan should be based on the doses of the individual components of the combination at the time of switching.</p><p><em><u>Special populations</u></em></p><p><em>Elderly (aged 65 years or older)</em></p><p>No dose adjustment is necessary for elderly patients. Caution is required when increasing the dosage. Limited information is available on use in the very elderly patients.</p><p><em>Renal impairment</em></p><p>No dose adjustment is required for patients with mild to moderate renal impairment. Monitoring of potassium levels and creatinine is advised in moderate renal impairment. Caution is advised because of limited experience available in patients with severe or end-stage renal impairment (Clcr&lt;15 mL/min) or on haemodialysis.</p><p>Changes in amlodipine plasma concentrations are not correlated with stage of renal impairment, therefore the usual dosage is recommended. Amlodipine and candesartan cilexetil are not dialysable. See also section 4.4.</p><p><em>Hepatic impairment</em></p><p>In patients with mild to moderate hepatic impairment Clodipan should be administered with caution. Clodipan is contraindicated in patients with severe hepatic impairment and/or cholestasis (see sections 4.3, 4.4 and 5.2).</p><p><em>Paediatric population</em></p><p>The safety and efficacy of Clodipan in children aged below 18 years have not been established. No data are available.</p><p><u>Methods of administration</u></p><p>Oral use.</p><p>Clodipan can be taken with or without food. It is recommended to take Clodipan with some liquid.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to the active substances, to dihydropyridine derivatives, or to any of the excipients listed in section 6.1.
•	Second and third trimesters of pregnancy (see sections 4.4 and 4.6);
•	Severe hepatic impairment and biliary obstructive disorders and/or cholestasis;
•	Shock (including cardiogenic shock);
•	Severe hypotension;
•	Obstruction of the outflow-tract of the left ventricle (e.g. high grade aortic stenosis)
•	Haemodynamically unstable heart failure after acute myocardial infarction;
•	The concomitant use of Clodipan with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 mL/min/1.73 m2) (see sections 4.5 and 5.1).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Candesartan</p><p><em>Pregnancy</em></p><p>Angiotensin II receptor antagonists should not be initiated during pregnancy. Unless continued angiotensin II receptor antagonist therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with angiotensin II receptor antagonists should be stopped immediately, and, if appropriate, alternative therapy should be started (see section 4.3 and 4.6).</p><p><em>Dual blockade of the renin-angiotensin-aldosterone system (RAAS)</em></p><p>There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and 5.1).</p><p>If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure. ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.</p><p><em>Renal impairment</em></p><p>As with other agents inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible patients treated with candesartan.</p><p>When candesartan is used in hypertensive patients with renal impairment, periodic monitoring of serum potassium and creatinine levels is recommended. There is limited experience in patients with very severe or end-stage renal disease (Clcr &lt; 15 mL/min). In these patients candesartan should be carefully titrated with thorough monitoring of blood pressure.</p><p>Evaluation of patients with heart failure should include periodic assessments of renal function, especially in elderly patients 75 years or older, and patients with impaired renal function. During dose titration of candesartan, monitoring of serum creatinine and potassium is recommended. Clinical trials in heart failure did not include patients with serum creatinine &gt; 265 &mu;mol/L (&gt; 3 mg/dL).</p><p><em>Concomitant therapy with an ACE-inhibitor in heart failure</em></p><p>The risk of adverse reactions, especially hypotension, hyperkalaemia and decreased renal function (including acute renal failure), may increase when Clodipan is used in combination with an ACE- inhibitor (see section 4.8). Triple combination of an ACE-inhibitor, a mineralocorticoid receptor antagonist and candesartan is also not recommended. Use of these combinations should be under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.</p><p>ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.</p><p><em>Haemodialysis</em></p><p>During dialysis the blood pressure may be particularly sensitive to AT1-receptor blockade as a result of reduced plasma volume and activation of the renin-angiotensin-aldosterone system. Therefore, candesartan should be carefully titrated with thorough monitoring of blood pressure in patients on haemodialysis.</p><p><em>Renovascular hypertension</em></p><p>There is an increased risk of severe hypotension and renal insufficiency when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney when treated with medicinal products that affect the renin-angiotensin-aldosterone system.</p><p><em>Kidney transplantation</em></p><p>There is no experience regarding the administration of candesartan in patients with a recent kidney transplantation.</p><p><em>Hypotension</em></p><p>Symptomatic hypotension, especially after the first dose, may occur in patients who are volume and/or sodium depleted by e.g. vigorous diuretic therapy, dietary salt restriction, diarrhoea or vomiting. Such conditions should be corrected before the administration of candesartan. If hypotension occurs with Clodipan, the patient should be placed in the supine position and, if necessary, given an intravenous infusion of sodium chloride 9 mg/ml (0.9%) solution for infusion. Treatment can be continued once blood pressure has been stabilised.</p><p><em>Anaesthesia and surgery</em></p><p>Hypotension may occur during anaesthesia and surgery in patients treated with angiotensin II antagonists due to blockade of the renin-angiotensin system. Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors.</p><p><em>Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy</em></p><p>As with other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.</p><p><em>Primary aldosteronism</em></p><p>Patients with primary aldosteronism generally will not respond to antihypertensive medicinal products acting through inhibition of the renin-angiotensin system. Therefore, the use of candesartan is not recommended.</p><p><em>Hyperkalaemia</em></p><p>The use of medicinal products that affect the renin-angiotensin-aldosterone system may cause hyperkalaemia. Hyperkalaemia may be fatal in the elderly, in patients with renal insufficiency, in diabetic patients, in patients concomitantly treated with other medicinal products that may increase potassium levels, and/or in patients with intercurrent events.</p><p>Before considering the concomitant use of medicinal products that affect the renin-angiotensin aldosterone system, the benefit risk ratio should be evaluated. The main risk factors for hyperkalaemia to be considered are:</p><p>-&nbsp; Diabetes mellitus,</p><p>-&nbsp; Renal impairment,</p><p>-&nbsp; Age (&gt;70 years),</p><p>-&nbsp; Combination with one or more other medicinal products that affect the renin-angiotensin aldosterone system and/or potassium supplements.</p><p>-&nbsp; Salt substitutes containing potassium,</p><p>-&nbsp; Potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs, including selective COX-2 inhibitors), heparin, immunosuppressants (cyclosporin or tacrolimus), and trimethoprim.</p><p>-&nbsp; Intercurrent events, in particular dehydratation, acute cardiac decompensation, metabolic acidosis, worsening of renal function, sudden worsening of the renal condition (e.g. infectious diseases), cellular lysis (e.g. acute limb ischemia, rhabdomyolysis, extensive trauma).</p><p>Serum potassium should be monitored closely in these patients (see section 4.5).</p><p><em>General</em></p><p>In patients whose vascular tone and renal function depend predominantly on the activity of the renin angiotensin-aldosterone system (e.g. patients with severe congestive heart failure or underlying renal disease, including renal artery stenosis), treatment with medicinal products that affect this system has been associated with acute hypotension, hyperazotaemia, oliguria, or rarely acute renal failure (see section 4.8). As with any antihypertensive medicinal product, excessive reduction of blood pressure in patients with ischaemic cardiomyopathy or ischaemic cardiovascular disease could result in a myocardial infarction or stroke.</p><p>The antihypertensive effect of candesartan may be enhanced by other medicinal products with blood pressure lowering properties, whether prescribed as an antihypertensive or prescribed for other indications.</p><p>Amlodipine</p><p><em>Hypertensive crisis</em></p><p>The safety and efficacy of amlodipine in hypertensive crisis has not been established.</p><p><em>Cardiac failure</em></p><p>Patients with heart failure should be treated with caution. In a long-term, placebo controlled study in patients with severe heart failure (NYHA class III and IV) the reported incidence of pulmonary oedema was higher in the amlodipine-treated group than in the placebo group.</p><p>Calcium channel blockers, including amlodipine ,should be used with caution in patients with congestive heart failure, as they may increase the risk of future cardiovascular events and mortality (see section 5.1).</p><p><em>Hepatic impairment</em></p><p>Amlodipine half-life is prolonged and AUC values are higher in patients with impaired liver function; dose recommendations have not been established. Clodipan should therefore be used with caution in patients with mild to moderate hepatic impairment. For severe hepatic impairment, see section 4.3.</p><p><em>Elderly (aged 65 years or older)</em></p><p>In the elderly increase of the dosage should take place with care (see sections 4.2 and 5.2).</p><p><em>Renal failure</em></p><p>Amlodipine may be used in such patients at usual doses. Changes in amlodipine plasma concentrations are not correlated with degree of renal impairment. Amlodipine is not dialysable.</p><p><em>Lactose intolerance</em></p><p>This medicinal product contains lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interactions between the two components of this fixed dose combinations have been observed in clinical studies.</p><p><u>Interactions linked to <em>candesartan/amlodipine </em>to be taken into account with concomitant use.</u></p><p><em>Other antihypertensive medicinal products</em></p><p>The blood pressure lowering effect of Clodipan can be increased by concomitant use of other antihypertensive medicinal products.</p><p><em>Medicinal products with blood pressure lowering potential</em></p><p>Based on their pharmacological properties it can be expected that the following medicinal products may potentiate the hypotensive effects of all antihypertensives including Clodipan, e.g. baclofen, amifostine, neuroleptics or antidepressants. Furthermore, orthostatic hypotension may be aggravated by alcohol.</p><p><em>Corticosteroids (systemic use)</em></p><p>Reduction of the antihypertensive effect.</p><p><u>Interactions linked to candesartan</u></p><p>Compounds which have been investigated in clinical pharmacokinetic studies include hydrochlorothiazide, warfarin, digoxin, oral contraceptives (i.e. ethinylestradiol/levonorgestrel), glibenclamide, nifedipine and enalapril. No clinically significant pharmacokinetic interactions with these medicinal products have been identified.</p><p><em>Potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium, or other medicinal products (e.g. heparin) that may increase potassium level</em></p><p>Concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium, or other medicinal products (e.g. heparin) may increase potassium levels. Monitoring of potassium should be undertaken as appropriate (see section 4.4).</p><p><em>Lithium</em></p><p>Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors. A similar effect may occur with AIIRAs. Use of candesartan with lithium is not recommended. If the combination proves necessary, careful monitoring of serum lithium levels is recommended.</p><p><em>NSAIDs</em></p><p>When AIIRAs are administered simultaneously with non-steroidal anti-inflammatory drugs (NSAIDs) (i.e. selective COX-2 inhibitors, acetylsalicylic acid (&gt; 3 g/day) and non-selective NSAIDs), attenuation of the antihypertensive effect may occur.</p><p>As with ACE inhibitors, concomitant use of AIIRAs and NSAIDs may lead to an increased risk of worsening of renal function, including possible acute renal failure, and an increase in serum potassium, especially in patients with poor pre-existing renal function. The combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated</p><p>and consideration should be given to monitoring renal function after initiation of concomitant therapy, and periodically thereafter.</p><p><em>Dual blockade of the renin-angiotensin-aldosterone-system (RAAS)</em></p><p>Clinical trial data has shown that dual blockade of the RAAS through the combined use of ACE- inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).</p><p><u>Interactions linked to amlodipine</u></p><p><em><u>Effects of other medicinal products on amlodipine:</u></em></p><p><em>CYP3A4 inhibitors</em></p><p>Concomitant use of amlodipine with strong or moderate CYP3A4 inhibitors (protease inhibitors, azole antifungals, macrolides like erythromycin or clarithromycin, verapamil or diltiazem) may give rise to significant increase in amlodipine exposure. The clinical translation of these pharmacokinetic (PK) variations may be more pronounced in the elderly. Clinical monitoring and dose adjustment may thus be required.</p><p>Clarithromycin is an inhibitor of CYP3A4. There is an increased risk of hypotension in patients receiving clarithromycin with amlodipine. Close observation of patients is recommended when amlodipine is co-administered with clarithromycin.</p><p><em>CYP3A4 inducers</em></p><p>Upon co-administration of known inducers of the CYP3A4, the plasma concentration of amlodipine may vary. Therefore, blood pressure should be monitored and dose regulation considered both during and after concomitant use particularly with strong CYP3A4 inducers (e.g. rifampicin, <em>Hypericum perforatum</em>).</p><p>Administration of amlodipine with grapefruit or grapefruit juice is not recommended as bioavailability may be increased in some patients resulting in increased blood pressure lowering effects.</p><p><em>Dantrolene (infusion)</em></p><p>In animals, lethal ventricular fibrillation and cardiovascular collapse were observed in association with hyperkalemia after administration of verapamil and intravenous dantrolene. Due to risk of hyperkalemia, it is recommended that the co-administration of calcium channel blockers such as amlodipine be avoided in patients susceptible to malignant hyperthermia and in the management of malignant hyperthermia.</p><p><em><u>Effects of amlodipine on other medicinal products:</u></em></p><p><em>Tacrolimus</em></p><p>There is a risk of increased tacrolimus blood levels when co-administered with amlodipine. In order to avoid toxicity of tacrolimus, administration of amlodipine in a patient treated with tacrolimus requires monitoring of tacrolimus blood levels and dose adjustment of tacrolimus when appropriate.</p><p><em>Cyclosporine</em></p><p>No drug interaction studies have been conducted with cyclosporine and amlodipine in healthy volunteers or other populations with the exception of renal transplant patients, where variable trough concentration increases (average 0% - 40%) of cyclosporine were observed.</p><p>Consideration should be given for monitoring cyclosporine levels in renal transplant patients on amlodipine, and cyclosporine dose reductions should be made as necessary.</p><p><em>Simvastatin</em></p><p>Co-administration of multiple doses of 10 mg of amlodipine with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone. The dose of simvastatin to be limited to 20 mg daily in patients on amlodipine.</p><p>In clinical interaction studies, amlodipine did not affect the pharmacokinetics of atorvastatin, digoxin, or warfarin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p><em><u>Linked to candesartan/amlodipine</u></em></p><p>Clodipan is not recommended during the first trimester of pregnancy as no data are available and safety profile has not been established for both amlodipine and candesartan. Use in early pregnancy is only recommended when there is no safer alternative and when the disease itself carries greater risk for the mother and foetus.</p><p>Clodipan is contraindicated during the second and third trimesters of pregnancy due to candesartan content.</p><p><em><u>Linked to candesartan</u></em></p><p>The use of AIIRAs is contraindicated during the second and third trimesters of pregnancy (see sections</p><p>4.3 and 4.4). Exposure to AIIRA therapy during the second and third trimesters is known to induce human foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see section 5.3).</p><p>Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of foetal renal function and skull is recommended.</p><p>The use of AIIRAs is not recommended during the first trimester of pregnancy (see section 4.4). Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with AIIRAs, similar risks may exist for this class of drugs.</p><p>Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately and, if appropriate, alternative therapy should be started.</p><p>Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see sections 4.3 and 4.4).</p><p><em><u>Linked to amlodipine</u></em></p><p>The safety of amlodipine in human pregnancy has not been established.</p><p>In animal studies, reproductive toxicity was observed at high doses (see section 5.3).</p><p><u>Breast-feeding</u></p><p><em><u>Linked to candesartan/amlodipine</u></em></p><p>Because no information is available regarding the use of candesartan and amlodipine during breast- feeding, it is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.</p><p><em><u>Linked to amlodipine</u></em></p><p>Amlodipine is excreted in human milk. The proportion of the maternal dose received by the infant has been estimated with an interquartile range of 3 &ndash; 7%, with a maximum of 15%. The effect of amlodipine on infants is unknown. A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with amlodipine should be made taking into account the benefit of breast-feeding to the child and the benefit of amlodipine therapy to the mother.</p><p><u>Fertility</u></p><p><em><u>Linked to candesartan/amlodipine</u></em></p><p>No information is available regarding potential effect of candesartan and amlodipine on fertility.</p><p><em><u>Linked to candesartan</u></em></p><p>Animal studies have shown that candesartan cilexetil had no adverse effect on fertility in rats (see section 5.3)</p><p><em><u>Linked to amlodipine</u></em></p><p>Reversible biochemical changes in the head of spermatozoa have been reported in some patients treated by calcium channel blockers. Clinical data are insufficient regarding the potential effect of amlodipine on fertility. In one rat study, adverse effects were found on male fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects of candesartan on the ability to drive and use machines have been performed. However, it should be taken into account that occasionally dizziness or weariness may occur during treatment with candesartan.</p><p>Amlodipine can have minor or moderate influence on the ability to drive and use machines. If patients taking amlodipine suffer from dizziness, headache, fatigue or nausea the ability to react may be impaired. Caution is recommended especially at the start of treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Summary of the safety profile</em></p><p><u>Fixed dose combination</u></p><p>No clinical studies have been performed. Undesirable effects observed for particular active ingredients are described below.</p><p>Adverse reactions previously reported with one of the individual components (candesartan or amlodipine) may be potential adverse reactions with Clodipan as well, even if not observed in clinical trials or during the post-marketing period.</p><p><u>Candesartan</u></p><p><em>Treatment of hypertension</em></p><p>In controlled clinical studies with candesartan for treatment of hypertension adverse reactions were mild and transient. The overall incidence of adverse events showed no association with dose or age. Withdrawals from treatment due to adverse events were similar with candesartan cilexetil (3.1%) and placebo (3.2%).</p><p>In a pooled analysis of clinical trial data of hypertensive patients, adverse reactions with candesartan cilexetil were defined based on an incidence of adverse events with candesartan cilexetil at least 1% higher than the incidence seen with placebo. By this definition, the most commonly reported adverse reactions were dizziness/vertigo, headache and respiratory infection.</p><p><u>Amlodipine</u></p><p>The most commonly reported adverse reactions during treatment were oedema (very common) somnolence, dizziness, headache, palpitations, flushing, abdominal pain, nausea, ankle swelling, and fatigue (common).</p><p><em><u>Tabulated list of adverse reactions</u></em></p><p>The frequencies used in the tables throughout section 4.8 are:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; very common (&ge; 1/10),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; common (&ge; 1/100 to &lt; 1/10),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; uncommon (&ge; 1/1,000 to &lt; 1/100),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; rare (&ge; 1/10,000 to &lt; 1/1,000)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; very rare (&lt; 1/10,000),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;not known (cannot be estimated from the available data).</p><p><u>Candesartan</u></p><p>The Table 1 below presents adverse reactions from clinical trials and post-marketing experience.</p><p>Table 1</p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t202" coordsize="21600,21600" o:spt="202"
 path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
 margin-left:70.8pt;margin-top:38.1pt;width:453.95pt;height:39.4pt;z-index:15728640;
 mso-position-horizontal-relative:page' filled="f" stroked="f">
 <v:textbox inset="0,0,0,0"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td>&nbsp;</td></tr></tbody></table></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:795px"><tbody><tr><td style="vertical-align:top; width:311px"><p><strong>MedDRA System Organ Class</strong></p></td><td style="vertical-align:top; width:100px"><p><strong>Frequency</strong></p></td><td style="vertical-align:top; width:378px"><p><strong>Undesirable Effect</strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top; width:311px"><p>Infections and infestations</p></td><td style="vertical-align:top; width:100px"><p>Common</p></td><td style="vertical-align:top; width:378px"><p>Respiratory infection</p></td></tr><tr><td style="vertical-align:top; width:311px"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top; width:100px"><p>Very rare</p></td><td style="vertical-align:top; width:378px"><p>Leukopenia, neutropenia, agranulocytosis</p></td></tr><tr><td style="vertical-align:top; width:311px"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top; width:100px"><p>Very rare</p></td><td style="vertical-align:top; width:378px"><p>Hyperkalaemia, hyponatraemia</p></td></tr><tr><td style="vertical-align:top; width:311px"><p>Nervous system disorders</p></td><td style="vertical-align:top; width:100px"><p>Common</p></td><td style="vertical-align:top; width:378px"><p>Dizziness/vertigo, headache</p></td></tr><tr><td style="vertical-align:top; width:311px"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top; width:100px"><p>Very rare</p></td><td style="vertical-align:top; width:378px"><p>Cough</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:311px"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top; width:100px"><p>Very rare</p></td><td style="vertical-align:top; width:378px"><p>Nausea</p></td></tr><tr><td style="vertical-align:top; width:100px"><p>Not known</p></td><td style="vertical-align:top; width:378px"><p>Diarrhoea</p></td></tr><tr><td style="vertical-align:top; width:311px"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top; width:100px"><p>Very rare</p></td><td style="vertical-align:top; width:378px"><p>Increased liver enzymes, abnormal hepatic function, hepatitis</p></td></tr><tr><td style="vertical-align:top; width:311px"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top; width:100px"><p>Very rare</p></td><td style="vertical-align:top; width:378px"><p>Angioedema, rash, urticaria, pruritus</p></td></tr><tr><td style="vertical-align:top; width:311px"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top; width:100px"><p>Very rare</p></td><td style="vertical-align:top; width:378px"><p>Back pain, arthralgia, myalgia</p></td></tr><tr><td style="vertical-align:top; width:311px"><p>Renal and urinary disorders</p></td><td style="vertical-align:top; width:100px"><p>Very rare</p></td><td style="vertical-align:top; width:378px"><p>Renal impairment, including renal failure in susceptible patients</p></td></tr></tbody></table><p><em>Laboratory findings</em></p><p>As for other inhibitors of the renin-angiotensin-aldosterone system, small decreases in haemoglobin have been seen. No routine monitoring of laboratory variables is usually necessary for patients receiving candesartan. However, in patients with renal impairment, periodic monitoring of serum potassium and creatinine levels is recommended.</p><p><u>Amlodipine</u></p><p>Within each frequency grouping, adverse reactions in Table 2 are presented in order of decreasing seriousness.</p><p>Table 2</p><table border="1" cellspacing="0" cellpadding="0" style="width:767px"><tbody><tr><td style="vertical-align:top; width:310px"><p><strong>MedDRA System organ class</strong></p></td><td style="vertical-align:top; width:108px"><p><strong>Frequency</strong></p></td><td style="vertical-align:top; width:346px"><p><strong>Adverse reactions</strong></p></td></tr><tr><td style="vertical-align:top; width:310px"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top; width:108px"><p>Very rare</p></td><td style="vertical-align:top; width:346px"><p>Leukocytopenia, thrombocytopenia</p></td></tr><tr><td style="vertical-align:top; width:310px"><p>Immune system disorders</p></td><td style="vertical-align:top; width:108px"><p>Very rare</p></td><td style="vertical-align:top; width:346px"><p>Allergic reactions</p></td></tr><tr><td style="vertical-align:top; width:310px"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top; width:108px"><p>Very rare</p></td><td style="vertical-align:top; width:346px"><p>Hyperglycaemia</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:310px"><p>Psychiatric disorders</p></td><td style="vertical-align:top; width:108px"><p>Uncommon</p></td><td style="vertical-align:top; width:346px"><p>Insomnia, mood changes (including anxiety), depression</p></td></tr><tr><td style="vertical-align:top; width:108px"><p>Rare</p></td><td style="vertical-align:top; width:346px"><p>Confusion</p></td></tr><tr><td rowspan="4" style="vertical-align:top; width:310px"><p>&nbsp;</p><p>Nervous system disorders</p></td><td style="vertical-align:top; width:108px"><p>Common</p></td><td style="vertical-align:top; width:346px"><p>Somnolence, dizziness, headache (especially at the beginning of the treatment)</p></td></tr><tr><td style="vertical-align:top; width:108px"><p>Uncommon</p></td><td style="vertical-align:top; width:346px"><p>Tremor, dysgeusia, syncope, hypoesthesia, paresthesia</p></td></tr><tr><td style="vertical-align:top; width:108px"><p>Very rare</p></td><td style="vertical-align:top; width:346px"><p>Hypertonia, peripheral neuropathy</p></td></tr><tr><td style="vertical-align:top; width:108px"><p>Not known</p></td><td style="vertical-align:top; width:346px"><p>Extrapyramidal disorder</p></td></tr><tr><td style="vertical-align:top; width:310px"><p>Eye disorders</p></td><td style="vertical-align:top; width:108px"><p>Common</p></td><td style="vertical-align:top; width:346px"><p>Visual disturbance (including diplopia)</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:768px"><tbody><tr><td style="vertical-align:top; width:310px"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top; width:107px"><p>Uncommon</p></td><td style="vertical-align:top; width:346px"><p>Tinnitus</p></td></tr><tr><td rowspan="3" style="vertical-align:top; width:310px"><p>Cardiac disorders</p></td><td style="vertical-align:top; width:107px"><p>Common</p></td><td style="vertical-align:top; width:346px"><p>Palpitations</p></td></tr><tr><td style="vertical-align:top; width:107px"><p>Uncommon</p></td><td style="vertical-align:top; width:346px"><p>Arrhythmia (including bradycardia, ventricular tachycardia and atrial fibrillation)</p></td></tr><tr><td style="vertical-align:top; width:107px"><p>Very rare</p></td><td style="vertical-align:top; width:346px"><p>Myocardial infarction</p></td></tr><tr><td rowspan="3" style="vertical-align:top; width:310px"><p>&nbsp;</p><p>Vascular disorders</p></td><td style="vertical-align:top; width:107px"><p>Common</p></td><td style="vertical-align:top; width:346px"><p>Flushing</p></td></tr><tr><td style="vertical-align:top; width:107px"><p>Uncommon</p></td><td style="vertical-align:top; width:346px"><p>Hypotension</p></td></tr><tr><td style="vertical-align:top; width:107px"><p>Very rare</p></td><td style="vertical-align:top; width:346px"><p>Vasculitis</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:310px"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top; width:107px"><p>Common</p></td><td style="vertical-align:top; width:346px"><p>Dyspnoea</p></td></tr><tr><td style="vertical-align:top; width:107px"><p>Uncommon</p></td><td style="vertical-align:top; width:346px"><p>Cough, rhinitis</p></td></tr><tr><td rowspan="3" style="vertical-align:top; width:310px"><p>&nbsp;</p><p>Gastrointestinal disorders</p></td><td style="vertical-align:top; width:107px"><p>&nbsp;</p><p>Common</p></td><td style="vertical-align:top; width:346px"><p>Abdominal pain, nausea, dyspepsia, altered bowel habits</p><p>(including diarrhoea and constipation)</p></td></tr><tr><td style="vertical-align:top; width:107px"><p>Uncommon</p></td><td style="vertical-align:top; width:346px"><p>Vomiting, dry mouth</p></td></tr><tr><td style="vertical-align:top; width:107px"><p>Very rare</p></td><td style="vertical-align:top; width:346px"><p>Pancreatitis, gastritis, gingival hyperplasia</p></td></tr><tr><td style="vertical-align:top; width:310px"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top; width:107px"><p>Very rare</p></td><td style="vertical-align:top; width:346px"><p>Hepatitis, jaundice, hepatic enzymes increased*</p></td></tr><tr><td rowspan="3" style="vertical-align:top; width:310px"><p>&nbsp;</p><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top; width:107px"><p>&nbsp;</p><p>Uncommon</p></td><td style="vertical-align:top; width:346px"><p>Alopecia, purpura, skin discolouration, hyperhidrosis, pruritus, rash, exanthema, urticaria</p></td></tr><tr><td style="vertical-align:top; width:107px"><p>Very rare</p></td><td style="vertical-align:top; width:346px"><p>Angioedema, erythema multiforme, urticaria, exfoliative dermatitis, Stevens- Johnson syndrome, Quincke oedema, photosensitivity</p></td></tr><tr><td style="vertical-align:top; width:107px"><p>Not known</p></td><td style="vertical-align:top; width:346px"><p>Toxic epidermal necrolysis</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:310px"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top; width:107px"><p>Common</p></td><td style="vertical-align:top; width:346px"><p>Ankle swelling</p></td></tr><tr><td style="vertical-align:top; width:107px"><p>Uncommon</p></td><td style="vertical-align:top; width:346px"><p>Arthralgia, myalgia, muscle cramps, back pain</p></td></tr><tr><td style="vertical-align:top; width:310px"><p>Renal and urinary disorders</p></td><td style="vertical-align:top; width:107px"><p>Uncommon</p></td><td style="vertical-align:top; width:346px"><p>Micturition disorder, nocturia, increased urinary frequency</p></td></tr><tr><td style="vertical-align:top; width:310px"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top; width:107px"><p>Uncommon</p></td><td style="vertical-align:top; width:346px"><p>Impotence, gynaecomastia</p></td></tr><tr><td rowspan="3" style="vertical-align:top; width:310px"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top; width:107px"><p>Very common</p></td><td style="vertical-align:top; width:346px"><p>Oedema</p></td></tr><tr><td style="vertical-align:top; width:107px"><p>Common</p></td><td style="vertical-align:top; width:346px"><p>Fatigue, asthenia</p></td></tr><tr><td style="vertical-align:top; width:107px"><p>Uncommon</p></td><td style="vertical-align:top; width:346px"><p>Chest pain, pain, malaise</p></td></tr><tr><td style="vertical-align:top; width:310px"><p>Investigations</p></td><td style="vertical-align:top; width:107px"><p>Uncommon</p></td><td style="vertical-align:top; width:346px"><p>Weight increase, weight decrease</p></td></tr></tbody></table><p>*mostly consistent with cholestasis</p><p><u>To reports any side effect(s):</u></p><p><strong>Saudi Arabia:</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td>&bull;The National Pharmacovigilance Centre (NPC):<br />&bull;SFDA Call Center: 19999<br />&bull;E-mail: npc.drug@sfda.gov.sa<br />&bull;Website: https://ade.sfda.gov.sa/</td></tr></tbody></table><p><strong>Other GCC States:</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>- Please contact the relevant competent authority.</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Symptoms</em></p><p>There is no experience of overdose with the fixed dose combination candesrtan/amlodipine in humans.</p><p><!--[if gte vml 1]><v:rect id="_x0000_s1026"
 style='position:absolute;left:0;text-align:left;margin-left:322.4pt;
 margin-top:11.45pt;width:2.75pt;height:1.1pt;z-index:-16303104;
 mso-position-horizontal-relative:page' fillcolor="black" stroked="f">
 <w:wrap anchorx="page"/>
</v:rect><![endif]--><img width="3" height="1" src="file:///C:/Users/aalzahrani/AppData/Local/Packages/oice_16_974fa576_32c1d314_309d/AC/Temp/msohtmlclip1/01/clip_image001.gif" />Available data suggest that gross overdose of amlodipine could result in excessive peripheral vasodilatation and possibly reflex tachycardia. Marked and probably prolonged systemic hypotension up to and including shock with fatal outcome have been reported.</p><p>Based on pharmacological considerations, the main manifestation of an overdose of candesartan is likely to be symptomatic hypotension and dizziness. In individual case reports of overdose (of up to 672mg candesartan cilexetil) patient recovery was uneventful.</p><p><em>Treatment</em></p><p>If symptomatic hypotension should occur, symptomatic treatment should be instituted and vital signs monitored. The patient should be placed supine with the legs elevated. If this is not sufficient, plasma volume should be increased by infusion of, for example, sodium chloride 9 mg/ml (0.9%) solution for infusion. Sympathomimetic medicinal products may be administered if the above-mentioned measures are not sufficient.</p><p>Candesartan is not removed by haemodialysis.</p><p>Clinically significant hypotension due to amlodipine overdose calls for active cardiovascular support including frequent monitoring of cardiac and respiratory function, elevation of extremities, and attention to circulating fluid volume and urine output.</p><p>A vasoconstrictor may be helpful in restoring vascular tone and blood pressure, provided that there is no contraindication to its use. Intravenous calcium gluconate may be beneficial in reversing the effects of calcium channel blockade.</p><p>Gastric lavage may be worthwhile in some cases. In healthy volunteers the use of charcoal up to 2 hours after administration of amlodipine 10 mg has been shown to reduce the absorption rate of amlodipine.</p><p>Since amlodipine is highly protein-bound, dialysis is not likely to be of benefit.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Agents acting on the renin-angiotensin system, angiotensin II antagonists and calcium channel blockers; ATC code: C09DB07</p><p>Clodipan combines two antihypertensive compounds with complementary mechanisms to control blood pressure in patients with essential hypertension: an angiotensin II receptor antagonist, candesartan cilexetil and a dihydropyridinic calcium channel blocker, amlodipine.</p><p>The combination of these substances has an additive antihypertensive effect, reducing blood pressure to a greater degree than either component alone.</p><p><em><u>Candesartan cilexetil</u></em></p><p><u>Mechanism of action</u></p><p>Angiotensin II is the primary vasoactive hormone of the renin-angiotensin-aldosterone system and plays a role in the pathophysiology of hypertension, heart failure and other cardiovascular disorders.</p><p>It also has a role in the pathogenesis of end organ hypertrophy and damage. The major physiological effects of angiotensin II, such as vasoconstriction, aldosterone stimulation, regulation of salt and water homeostasis and stimulation of cell growth, are mediated via the type 1 (AT1) receptor.</p><p>Candesartan cilexetil is a prodrug suitable for oral use. It is rapidly converted to the active substance, candesartan, by ester hydrolysis during absorption from the gastrointestinal tract. Candesartan is an AIIRA, selective for AT1 receptors, with tight binding to and slow dissociation from the receptor. It has no agonist activity.</p><p><u>Pharmacodynamic effects</u></p><p>Candesartan does not inhibit ACE, which converts angiotensin I to angiotensin II and degrades bradykinin. There is no effect on ACE and no potentiation of bradykinin or substance P.</p><p>In controlled clinical trials comparing candesartan with ACE inhibitors, the incidence of cough was lower in patients receiving candesartan cilexetil. Candesartan does not bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation. The antagonism of the angiotensin II (AT1) receptors results in dose related increases in plasma renin levels, angiotensin I and angiotensin II levels, and a decrease in plasma aldosterone concentration.</p><p><u>Clinical efficacy and safety</u></p><p><em><u>Hypertension</u></em></p><p>In hypertension, candesartan causes a dose-dependent, long-lasting reduction in arterial blood pressure. The antihypertensive action is due to decreased systemic peripheral resistance, without reflex increase in heart rate. There is no indication of seriousor exaggerated first dose hypotension or rebound effect after cessation of treatment.</p><p>After administration of a single dose of candesartan cilexetil, onset of antihypertensive effect generally occurs within 2 hours. With continuous treatment, most of the reduction in blood pressure with any dose is generally attained within four weeks and is sustained during long-term treatment. According to a meta-analysis, the average additional effect of a dose increase from 16 mg to 32 mg once daily was small. Taking into account the inter-individual variability, a more than average effect can be expected in some patients. Candesartan cilexetil once daily provides effective and smooth blood pressure reduction over 24 hours, with little difference between maximum and trough effects during the dosing interval.</p><p>The antihypertensive effect and tolerability of candesartan and losartan were compared in two randomised, double-blind studies in a total of 1,268 patients with mild to moderate hypertension. The trough blood pressure reduction (systolic/diastolic) was 13.1/10.5 mmHg with candesartan cilexetil 32 mg once daily and 10.0/8.7 mmHg with losartan potassium 100 mg once daily (difference in blood pressure reduction 3.1/1.8 mmHg, p&lt;0.0001/p&lt;0.0001).</p><p>When candesartan cilexetil is used together with hydrochlorothiazide, the reduction in blood pressure is additive. An increased antihypertensive effect is also seen when candesartan cilexetil is combined with amlodipine or felodipine.</p><p>Medicinal products that block the renin-angiotensin-aldosterone system have less pronounced antihypertensive effect in black patients (usually a low-renin population) than in non-black patients.</p><p>This is also the case for candesartan. In an open label clinical experience trial in 5,156 patients with diastolic hypertension, the blood pressure reduction during candesartan treatment was significantly less in black than non-black patients (14.4/10.3 mmHg vs 19.0/12.7 mmHg, p&lt;0.0001/p&lt;0.0001).</p><p>Candesartan increases renal blood flow and either has no effect on or increases glomerular filtration rate while renal vascular resistance and filtration fraction are reduced. In a 3-month clinical study in hypertensive patients with type 2 diabetes mellitus and microalbuminuria, antihypertensive treatment with candesartan cilexetil reduced urinary albumin excretion (albumin/creatinine ratio, mean 30%, 95%CI 15-42%). There is currently no data on the effect of candesartan on the progression to diabetic nephropathy.</p><p>The effects of candesartan cilexetil 8-16 mg (mean dose 12 mg), once daily, on cardiovascular morbidity and mortality were evaluated in a randomised clinical trial with 4,937 elderly patients (aged 70-89 years; 21% aged 80 or above) with mild to moderate hypertension followed for a mean of 3.7 years (Study on Cognition and Prognosis in the Elderly). Patients received candesartan cilexetil or placebo with other antihypertensive treatment added as needed. The blood pressure was reduced from 166/90 to 145/80 mmHg in the candesartan group, and from 167/90 to 149/82 mmHg in the control group. There was no statistically significant difference in the primary endpoint, major cardiovascular events (cardiovascular mortality, non-fatal stroke and non-fatal myocardial infarction). There were</p><p>26.7 events per 1000 patient-years in the candesartan group versus 30.0 events per 1000 patient-years in the control group (relative risk 0.89, 95%CI 0.75 to 1.06, p=0.19).</p><p><em><u>Dual blockade of the renin-angiotensin-aldosterone system (RAAS</u></em><em><u>)</u></em></p><p>Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker.</p><p>ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.</p><p>These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as compared to monotherapy was observed. Given their similar pharmacodynamic properties, these results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers.</p><p>ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy.</p><p>ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group than in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.</p><p><em><u>Amlodipine</u></em></p><p><u>Mechanism of action</u></p><p>Amlodipine is a calcium ion influx inhibitor of the dihydropyridine group (slow channel blocker or calcium ion antagonist) and inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle.</p><p>The mechanism of the antihypertensive action of amlodipine is due to a direct relaxant effect on vascular smooth muscle. The precise mechanism by which amlodipine relieves angina has not been fully determined but amlodipine reduces total ischaemic burden by the following two actions:</p><p>1)&nbsp; Amlodipine dilates peripheral arterioles and thus, reduces the total peripheral resistance (afterload) against which the heart works. Since the heart rate remains stable, this unloading of the heart reduces myocardial energy consumption and oxygen requirements.</p><p>2)&nbsp; The mechanism of action of amlodipine also probably involves dilatation of the main coronary arteries and coronary arterioles, both in normal and ischaemic regions. This dilatation increases myocardial oxygen delivery in patients with coronary artery spasm (Prinzmetal&#39;s or variant angina).</p><p><u>Pharmacodynamic effects</u></p><p>In patients with hypertension, once daily dosing provides clinically significant reductions of blood pressure in both the supine and standing positions throughout the 24 hour interval. Due to the slow onset of action, acute hypotension is not a feature of amlodipine administration.</p><p>In patients with angina, once daily administration of amlodipine increases total exercise time, time to angina onset, and time to 1 mm ST segment depression, and decreases both angina attack frequency and glyceryl trinitrate tablet consumption.</p><p>Amlodipine has not been associated with any adverse metabolic effects or changes in plasma lipids and is suitable for use in patients with asthma, diabetes, and gout.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Candesartan cilexetil</u></em></p><p><u>Absorption and distribution</u></p><p>Following oral administration, candesartan cilexetil is converted to the active substance candesartan. The absolute bioavailability of candesartan is approximately 40% after an oral solution of candesartan cilexetil. The relative bioavailability of the capsule formulation compared with the same oral solution is approximately 34% with very little variability. The estimated absolute bioavailability of the capsule is therefore 14%. The mean peak serum concentration (Cmax) is reached 3-4 hours following capsule intake. The candesartan serum concentrations increase linearly with increasing doses in the therapeutic dose range. No gender related differences in the pharmacokinetics of candesartan have been observed. The area under the serum concentration versus time curve (AUC) of candesartan is not significantly affected by food.</p><p>Candesartan is highly bound to plasma protein (more than 99%). The apparent volume of distribution of candesartan is 0.1 L/kg. The bioavailability of candesartan is not affected by food.</p><p><u>Biotransformation and elimination</u></p><p>Candesartan is mainly eliminated unchanged via urine and bile and only to a minor extent eliminated by hepatic metabolism (CYP2C9). Available interaction studies indicate no effect on CYP2C9 and CYP3A4. Based on <em>in vitro </em>data, no interaction would be expected to occur <em>in vivo </em>with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4. The terminal half-life of candesartan is approximately 9&nbsp; hours. There is no accumulation following multiple doses.</p><p>Total plasma clearance of candesartan is about 0.37 ml/min/kg, with a renal clearance of about</p><p>0.19 mL/min/kg. The renal elimination of candesartan is both by glomerular filtration and active tubular secretion. Following an oral dose of 14C-labelled candesartan cilexetil, approximately 26% of the dose is excreted in the urine as candesartan and 7% as an inactive metabolite while approximately 56% of the dose is recovered in the faeces as candesartan and 10% as the inactive metabolite.</p><p><u>Pharmacokinetics in special populations</u></p><p><em>Elderly (aged 65 years or older)</em></p><p>In the elderly (over 65 years) Cmax and AUC of candesartan are increased by approximately 50% and 80%, respectively in comparison to young subjects. However, the blood pressure response and the incidence of adverse events are similar after a given dose of candesartan in young and elderly patients (see section 4.2).</p><p><em>Renal impairment</em></p><p>In patients with mild to moderate renal impairment Cmax and AUC of candesartan increased during repeated dosing by approximately 50% and 70%, respectively, but t&frac12; was not altered, compared to patients with normal renal function. The corresponding changes in patients with severe renal impairment were approximately 50% and 110%, respectively. The terminal half life (t&frac12;) of candesartan was approximately doubled in patients with severe renal impairment. The AUC of candesartan in patients undergoing haemodialysis was similar to that in patients with severe renal impairment.</p><p><em>Hepatic impairment</em></p><p>In two studies, both including patients with mild to moderate hepatic impairment, there was an increase in the mean AUC of candesartan of approximately 20% in one study and 80% in the other study (see section 4.2). There is no experience in patients with severe hepatic impairment.</p><p><em><u>Amlodipine</u></em></p><p><u>Absorption and distribution</u></p><p>After oral administration of therapeutic doses, amlodipine is well absorbed with peak blood levels between 6-12 hours post dose. Absolute bioavailability has been estimated to be between 64% and 80%.</p><p>The volume of distribution is approximately 21 L/kg. <em>In vitro </em>studies have shown that approximately 97.5% of circulating amlodipine is bound to plasma proteins.</p><p>The bioavailability of amlodipine is not affected by food intake.</p><p><u>Biotransformation and elimination</u></p><p>The terminal plasma elimination half-life is about 35-50 hours and is consistent with once daily dosing. Amlodipine is extensively metabolised by the liver to inactive metabolites with 10% of the parent compound and 60% of metabolites excreted in the urine.</p><p><u>Pharmacokinetics in special populations</u></p><p><em>Hepatic impairment</em></p><p>Very limited clinical data are available regarding amlodipine administration in patients with hepatic impairment. Patients with hepatic insufficiency have decreased clearance of amlodipine resulting in a longer half-life and an increase in AUC of approximately 40-60%.</p><p><em>Renal impairment</em></p><p>Changes in amlodipine plasma concentrations are not correlated with degree of renal impairment. Amlodipine is not dialysable.</p><p><em>Elderly (aged 65 years or older)</em></p><p>The time to reach peak plasma concentrations of amlodipine is similar in elderly and younger subjects. Amlodipine clearance tends to be decreased with resulting increases in AUC and elimination half-life in elderly patients. Increases in AUC and elimination half-life in patients with congestive heart failure were as expected for the patient age group studied.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data available for the components of this fixed dose combination are reported below.</p><p><em><u>Candesartan</u> </em></p><p><em>Reproductive toxicty</em></p><p>There was no evidence of systemic or target organ toxicity at clinically relevant doses. In preclinical safety studies candesartan had effects on the kidneys and on red cell parameters at high doses in mice, rats, dogs and monkeys. Candesartan caused a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit). Effects on the kidneys (such as interstitial nephritis, tubular distension, basophilic tubules; increased plasma concentrations of urea and creatinine) were induced by candesartan which could be secondary to the hypotensive effect leading to alterations of renal perfusion. Furthermore, candesartan induced hyperplasia/hypertrophy of the juxtaglomerular cells.</p><p>These changes were considered to be caused by the pharmacological action of candesartan. For therapeutic doses of candesartan in humans, the hyperplasia/hypertrophy of the renal juxtaglomerular cells does not seem to have any relevance.</p><p>Foetotoxicity has been observed in late pregnancy (see section 4.6).</p><p><em>Carcinogenesis, mutagenesis</em></p><p>Data from <em>in vitro </em>and <em>in vivo </em>mutagenicity studies indicates that candesartan will not exert mutagenic or clastogenic activities under conditions of clinical use.</p><p>There was no evidence of carcinogenicity.</p><p><em><u>Amlodipine</u> Reproductive toxicity</em></p><p>Reproductive studies in rats and mice have shown delayed date of delivery, prolonged duration of labour and decreased pup survival at doses approximately 50 times greater than the maximum recommended dosage for humans based on mg/kg.</p><p><em>Impairment of fertility</em></p><p>There was no effect on the fertility of rats treated with amlodipine (males for 64 days and females 14 days prior to mating) at doses up to 10 mg/kg/day (8 times* the maximum recommended human dose of 10 mg on a mg/m2 basis). In another rat study in which male rats were treated with amlodipine besilate for 30 days at a dose comparable with the human dose based on mg/kg, decreased plasma follicle-stimulating hormone and testosterone were found as well as decreases in sperm density and in the number of mature spermatids and Sertoli cells.</p><p><em>Carcinogenesis, mutagenesis</em></p><p>Rats and mice treated with amlodipine in the diet for two years, at concentrations calculated to provide daily dosage levels of 0.5, 1.25, and 2.5 mg/kg/day showed no evidence of carcinogenicity. The highest dose (for mice, similar to, and for rats twice* the maximum recommended clinical dose of 10mg on a mg/m<sup>2</sup> basis) was close to the maximum tolerated dose for mice but not for rats.</p><p>Mutagenicity studies revealed no drug related effects at either the gene or chromosome levels.</p><p>*Based on patient weight of 50 kg</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Capsule content</u></p><p>Lactose monohydrate</p><p>Maize starch</p><p>Carmellose calcium</p><p>Macrogol Type 8000</p><p>Hydroxypropylcellulose/type: EXF, 250-800 cps</p><p>Hydroxypropylcellulose/type: LF, 65-175 cps</p><p>Magnesium stearate</p><p><u>Capsule shell (8 mg/5 mg, 8 mg /10 mg)</u></p><p>Quinoline yellow (E 104)</p><p>Iron oxide yellow (E 172)</p><p>Titanium dioxide (E 171)</p><p>Gelatin</p><p><u>Capsule shell (16 mg/5 mg)</u></p><p>Quinoline yellow (E 104)</p><p>Titanium dioxide (E 171)</p><p>Gelatin</p><p><u>Capsule shell (16 mg/10 mg)</u></p><p>Titanium dioxide (E 171)</p><p>Gelatin</p><p><u>Printing ink (8 mg/10 mg, 16 mg/ 5 mg)</u></p><p>Shellac (E904)</p><p>Iron oxide black (E172)</p><p>Propylene glycol</p><p>Ammonia solution, concentrated</p><p>Potassium hydroxide</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30 &ordm;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PA/Aluminium/PVC/Aluminium blisters in a carton box.</p><p>Pack sizes of 28 hard capsules (each blister contains 7 hard capsules).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Aspen Healthcare Malta Limited
89, Level 0
Triq is-Siggiewi
Is-Siggiewi SGW 2021
Malta
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                September 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>